{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"46"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"142"}],"units":"Participants"}],"groups":[{"description":"Participants received 5x10e6 pfu TG4001 subcutaneously along with 10 mg/kg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"BG000","title":"Phase I - TG4001 5x10e6 Pfu + Avelumab"},{"description":"Participants received 5x10e7 pfu TG4001 subcutaneously along with 10 mg/kg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"BG001","title":"Phase I - TG4001 5x10e7 Pfu + Avelumab"},{"description":"Participants received 5x10e7 pfu TG4001 subcutaneously along with 10 mg/kg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"BG002","title":"Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab"},{"description":"Participants received 5x10e7 pfu TG4001 subcutaneously along with 800 mg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"BG003","title":"Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab"},{"description":"Participants received 800 mg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"BG004","title":"Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab"},{"description":"Participants received 5x10e7 pfu TG4001 subcutaneously along with 800 mg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"BG005","title":"Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab"},{"description":"Participants received 800 mg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"BG006","title":"Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab"},{"description":"Total of all reporting groups","id":"BG007","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"37"},{"groupId":"BG004","value":"30"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"104"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"14"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"38"}],"title":">=65 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"46"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"142"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"45.0","upperLimit":"56.0","value":"52.0"},{"groupId":"BG001","lowerLimit":"51.0","upperLimit":"68.0","value":"65.5"},{"groupId":"BG002","lowerLimit":"48.0","upperLimit":"67.0","value":"56.0"},{"groupId":"BG003","lowerLimit":"50.0","upperLimit":"61.0","value":"57.0"},{"groupId":"BG004","lowerLimit":"46.5","upperLimit":"66.5","value":"56.5"},{"groupId":"BG005","lowerLimit":"41.0","upperLimit":"54.0","value":"43.0"},{"groupId":"BG006","lowerLimit":"57.0","upperLimit":"75.5","value":"67.5"},{"groupId":"BG007","lowerLimit":"48.0","upperLimit":"66.0","value":"56.0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"46"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"142"}],"units":"Participants"}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"125"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"17"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"46"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"142"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG007","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"46"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"142"}],"units":"Participants"}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"39"},{"groupId":"BG004","value":"37"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"127"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"46"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"142"}],"units":"Participants"}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"14"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"46"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"142"}],"units":"Participants"}],"title":"Spain"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"25"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"61"}],"title":"Cervical"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"52"}],"title":"Anal"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"10"}],"title":"Oropharyngeal"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"9"}],"title":"Vaginal"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"9"}],"title":"Vulvar"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}],"title":"Penile"}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"46"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"142"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Primary tumor location","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"47"}],"title":"ECOG Status 0"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"33"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"95"}],"title":"ECOG Status 1"}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"46"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"142"}],"units":"Participants"}]}],"description":"Measure Description:\n\nThe Eastern Cooperative Oncology Group (ECOG) score is an overall assessment of the functional/physical performance of the patient.\n\nScores are:\n\n0=Fully active, able to carry on all pre-disease performance without restriction. 1=Restricted in strenuous activity but ambulatory and able to carry out work of a sedentary nature.","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"In phase I and phase II part 1: all participants included and who received any amount of study treatment will be included in the SAF. Any participant who is assigned a participants number but does not receive any study treatment will not be included in the SAF.\n\nIn phase II part 2: all randomized participants who were administered at least one dose of IMP(s) according to the treatment allocated at randomization will be included in the SAF."}